Contract mfr. to shutter Buffalo plant; Astellas extends Micardis co-promo with Boehringer;

  @FiercePharma:  Did too much autonomy lead to J&J recalls? Article  | Follow @FiercePharma

> Contract Pharmaceuticals Limited says it will close its Buffalo plant by the end of next year because of a lack of business, leaving 260 employees out of work. Report

> Astellas Pharma said it will extend its co-promotion deal in Japan with Boehringer Ingelheim (BRI.YY) for the blood pressure-lowering drug, Micardis, for four years. Report

> Pharmacists are taking drug manufacturer GlaxoSmithKline to court over a New Zealand recall of a blood-thinning drug, saying they are bearing the company's expenses in carrying out the work. Report

> A doctor whose claims of links between vaccination and autism triggered a scientific storm before being widely discredited was struck off Britain's medical register on Monday for professional misconduct. Report

> Javelin Pharmaceuticals (JAV.A) said the U.K. unit of Therabel Pharma, which owns commercial rights to Javelin's post-operative pain drug Dyloject in the E.U., was withdrawing all batches of the injectable drug from the U.K. market. Report

> AstraZeneca has contributed $1 million toward expansion and renovation at Wilmington Hospital in Wilmington, Del. Report

> Sepracor won court approval to settle a lawsuit in which shareholders unsuccessfully sought more money in the company's $2.3 billion sale last year to Japan's Dainippon Sumitomo Pharma. Report

> Celgene (CELG) and Biogen Idec (BIIB) were among the drugmaker stocks moving Friday as investors digested the more than 4,000 study abstracts released ahead of a key cancer conference. Report

> U.K. supermarket chain Asda has started selling privately prescribed cancer drugs on a not-for-profit basis. Report

Biotech News

 @FierceBiotech: Venter team births world's first synthetic cell. Article | Follow @FierceBiotech

 @JohnCFierce:Any biotech looking for a piece of the $1B tax credit/grant better be ready to play. This money will be gone quickly. Article | Follow @JohnCFierce

> NormOxys gets $17.5M to fund PoC work on new drug class. News

> Quintiles lays off staffers in shift to emerging markets. Story

> Feds spell out the rules on $1B biotech windfall. Item

> GE brings $3B life sciences project to light. Article

> Treasury releases Therapeutic Discovery Credit guidance. Report

Biotech IT News

> NCI website aids cancer trial recruitment. Story

> Roche uses PK/PD modeling to screen compounds. Report

> Cato, Merge extend relationship. News

> CRO launches tech group for data capture solution. Article

> Ludwig Cancer Institute picks Medidata Rave. Item

> Researchers tackle randomized trial challenge. Story

And Finally... Acupuncture worked as well as Effexor in combating hot flashes and other menopausal symptoms that can accompany breast cancer treatments, and its benefits last longer without causing side effects, according to a small new study. Report